New Zealand Lacks Contemporary Data on Gut-Brain Disorders, Otago Review Finds

New Zealand lacks any contemporary data on disorders of gut-brain interaction, with the most recent prevalence study published in 2002, a University of Otago review in the New Zealand Medical Journal has found.

The scoping review, led by Dr Simone Bayer and colleagues Jody Miller and Nathan Berg, identified only four New Zealand studies reporting prevalence of these conditions — a group including irritable bowel syndrome (IBS) and functional dyspepsia — all limited to Wellington and Dunedin.

None captured data for Māori or Pacific peoples. Published Thursday, the paper warns that without local evidence, health planners cannot quantify demand on the health system or assess equity of access, Medical Xpress reported.

“People living with these conditions can experience significant and ongoing symptoms, yet we don’t have any strong contemporary evidence telling us how many New Zealanders are affected,” Dr Bayer said. “That means we are also unable to properly comprehend the scale of demand on our health system, or whether different groups of New Zealanders are experiencing these conditions and accessing care in different ways.”

Internationally, research from the United Kingdom and Australia — both operating comparable publicly funded health systems — using contemporary Rome IV diagnostic criteria found approximately 37 per cent of adults meet criteria for at least one disorder of gut-brain interaction.

Extrapolating UK direct healthcare cost estimates for IBS to a hypothetical one-third of New Zealand adults suggests direct costs of roughly NZ$1.6 billion annually, with total economic burden approaching 1 per cent of gross domestic product when productivity losses are included. Dr Bayer stressed this is a modelled proxy, not a direct measurement of New Zealand costs.

Story on The Morning Science
Photo: themorning.science

New Zealand Lacks Prevalence Data for over Two Decades

  • No local numbers: New Zealand has not measured how common these gut disorders are in over two decades, leaving clinicians and planners guessing.
  • Equity blind spot: There is zero prevalence data for Māori or Pacific communities, making it impossible to know if care is reaching those who need it.

Rome IV Criteria Define Current Diagnostic Standard

Disorders of gut-brain interaction (DGBI), formerly termed functional gastrointestinal disorders, are defined by chronic gastrointestinal symptoms — abdominal pain, altered bowel habits, indigestion — without identifiable structural or biochemical pathology.

The Otago review, published with DOI 10.26635/6965.7608, searched Ovid Embase and PubMed on 10 December 2025. It included New Zealand studies regardless of diagnostic criteria but restricted UK and Australian data to those using Rome IV criteria, the current global standard updated in 2016.

The four New Zealand studies identified predate Rome IV, relying on earlier Manning or Rome I/II criteria, which complicates direct comparison with the 37 per cent prevalence benchmark established in the UK and Australia.

Two small, industry-linked New Zealand cost studies were identified, but the review deemed them insufficient for national modelling. The researchers argue that the diagnostic criteria shift alone necessitates new prevalence work, as Rome IV reclassifies certain symptom patterns and removes the requirement for “discomfort” as a distinct qualifier from pain.

Equity Gap: The Missing Māori and Pacific Data

The absence of prevalence data for Māori and Pacific peoples is the review’s most pointed finding. Te Whatu Ora — Health New Zealand has prioritised equity in its interim Māori Health Action Plan, yet the evidence base for DGBI contains no Māori-specific estimates.

The authors state future research must be designed from inception to produce Māori-specific prevalence and be undertaken in partnership with Māori health researchers and communities, aligning with Te Ara Tika guidelines for Māori research ethics.

“The researchers found the evidence gap is particularly concerning for Māori, with no study identified measuring DGBI prevalence in Māori,” the University of Otago newsroom release noted. “They say future research should be designed from the outset to produce Māori-specific estimates and be undertaken in partnership with Māori health researchers and communities.”

Economic Modelling and Health System Implications

Using UK mean direct costs per IBS patient applied to an estimated one-third of New Zealand’s adult population, the review models direct healthcare utilisation costs at NZ$1.6 billion annually. Indirect costs — absenteeism, presenteeism, early workforce exit — likely push the total burden toward 1 per cent of GDP, consistent with estimates from comparable countries published in the New Zealand Medical Journal (2026).

Metric New Zealand (Current Evidence) UK / Australia (Rome IV Data)
Adult Prevalence Estimate Unknown ~37%
Māori / Pacific Data None Limited / Emerging
Direct Cost Estimate (Annual) Not measured NZ$1.6B (modelled proxy)
Diagnostic Criteria Used Manning / Rome I-II Rome IV

The review highlights that DGBI drives repeated primary care presentations, specialist referrals, endoscopic investigations, and polypharmacy — including neuromodulators (low-dose tricyclic antidepressants), gut-directed hypnotherapy, and secretagogues — without a national framework to guide resource allocation. The authors call for a dedicated national prevalence study using Rome IV criteria, linked to integrated data infrastructure (Statistics NZ Integrated Data Infrastructure) for a formal cost-of-illness analysis.

Alarm Features Requiring Urgent Medical Investigation

While DGBI are diagnosed by symptom criteria (Rome IV) after excluding organic disease, certain “alarm features” mandate urgent investigation to rule out structural pathology such as inflammatory bowel disease, coeliac disease, or colorectal cancer. Consult a general practitioner promptly if you experience:

  • Unintentional weight loss greater than 5 per cent of body weight.
  • Rectal bleeding or iron-deficiency anaemia.
  • Nocturnal symptoms waking you from sleep.
  • Onset of new symptoms after age 50.
  • Family history of gastrointestinal malignancy or inflammatory bowel disease.

These features are contraindications for a purely symptom-based DGBI diagnosis without further workup. Management of confirmed DGBI is stepped: dietary modification (low FODMAP diet under dietitian supervision), psychological therapies (gut-directed hypnotherapy, CBT), and neuromodulators. Opioids are contraindicated for chronic functional abdominal pain due to risk of narcotic bowel syndrome and dependence.

The University of Otago, New Zealand’s oldest university, was founded by ordinance of the Otago Provincial Council in 1869 and opened for teaching in 1871. Based in Dunedin, it operates additional health sciences campuses in Christchurch and Wellington.

In 1897, it became the first university in Australasia to admit women to a law degree, with Ethel Benjamin graduating LLB and becoming the first woman in the British Empire to appear as counsel in court. As of 2024, the university reported a student headcount of 21,315.

Dr Bayer said the findings demonstrate the need for dedicated research investment. “We need to know how common these conditions really are in Aotearoa, how they affect different communities, and what they are costing patients and the health system,” she said. “A national prevalence study, alongside a formal analysis of health care costs using New Zealand health data, would give us the evidence needed to improve diagnosis, treatment and planning.”

References

  • Bayer S, Miller J, Berg N. Disorders of gut–brain interaction in Aotearoa New Zealand: a long-standing evidence gap with unmeasured health and economic consequences. New Zealand Medical Journal. 2026;139(1645). DOI: 10.26635/6965.7608
  • Drossman DA, Hasler WL. Rome IV Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257-1261.
  • Black CJ, et al. Global prevalence of functional gastrointestinal disorders (FGIDs) and disorders of gut-brain interaction (DGBIs) in adults: a systematic review and meta-analysis. Gut. 2021;70(11):2102-2111.
  • Jones MP, et al. The burden of functional gastrointestinal disorders in Australia. Alimentary Pharmacology & Therapeutics. 2021;53(10):1120-1130.
  • Te Whatu Ora. Interim Māori Health Action Plan 2023-2024. Wellington: Te Whatu Ora; 2023.
Photo of author

Health Desk

Health Desk at Archyde.

ESPN Publishes Women’s Basketball Feast Week Guide Highlighting 26 Games

Dakota and Elle Fanning Star Together for First Time in ‘The Nightingale’ Teaser Trailer